John Chan, MD

Articles

Adverse Event Management and Emerging Therapies in Ovarian Cancer: PARPi Challenges and the Role of ADCs

January 15th 2025

Panelists discuss the most common adverse events associated with PARP inhibitor (PARPi) therapy in ovarian cancer and strategies for mitigating or managing these adverse effects. They also review recent data on antibody-drug conjugates (ADCs) in ovarian cancer, including the evolving role of mirvetuximab soravtansine in the FORWARD II trial, and other ADCs such as luveltamab tazevibulin and rinatabart sesutecan, highlighting promising findings from studies presented at ESMO 2024. The session concludes with a discussion on future perspectives in ovarian cancer treatment, offering insights into emerging therapies and the evolving landscape.

Emerging Maintenance Strategies in Advanced/Metastatic Disease: Insights on Combination Therapies and Overcoming PARP Inhibitor Resistance

January 8th 2025

Panelists discuss PARP inhibitor resistance in ovarian cancer and explore strategies to overcome this challenge, including findings from the PRESERVE-004 trial evaluating gotistobart plus pembrolizumab, along with other potential treatment options. Additionally, they review insights from the SOPRANO trial regarding the management of oligometastases or oligoprogression in ovarian cancer.

Overview of PRIMA - Niraparib 1L Maintenance

January 1st 2025

Panelists discuss the implications of PFS and OS data from the PRIMA trial evaluating niraparib as first-line maintenance therapy in advanced ovarian cancer, and the impact of these findings on the treatment paradigm, as well as new insights from the GEICO-88R study on long-term responders to niraparib. They also explore emerging maintenance strategies, including IO combination therapies and hormonal therapies, with a focus on ongoing trials such as rucaparib plus nivolumab, atezolizumab plus bevacizumab, and olaparib plus cediranib.

Optimizing PARP Inhibitor Duration

December 25th 2024

Panelists discuss how the duration of PARP inhibitor (PARPi) therapy typically differs between the first-line and second-line settings in advanced ovarian cancer treatment.

Brief Overview of Frontline Maintenance Therapy for Advanced Ovarian Cancer

December 18th 2024

Panelists discuss how frontline maintenance therapy options for advanced ovarian cancer are influenced by key factors, such as a patient’s HRD status, and when a combination approach with PARP inhibitors and bevacizumab might be preferred over monotherapy.

Role of Genomic Instability Scores in Treatment Selection

December 11th 2024

Panelists discuss how genomic instability scores, including HRD vs HRP profiles, influence treatment selection and sequencing in ovarian cancer, particularly in guiding the use of PARP inhibitors and other targeted therapies in the maintenance setting, and how these scores may prompt adjustments to standard treatment approaches.

Biomarker Testing in Advanced Ovarian Cancer

December 4th 2024

Panelists discuss how biomarker testing for advanced ovarian cancer, including when and which biomarkers to test (such as HRD), plays a crucial role in guiding treatment decisions and personalizing patient care.